Abstract

Studying survivorship and causes of death in patients with advanced or metastatic cancer remains an important task. We characterize the causes of death among patients with metastatic cancer, across 13 cancer types and 25 non-cancer causes and predict the risk of death after diagnosis from the diagnosed cancer versus other causes (e.g., stroke, heart disease, etc.). Among 1,030,937 US (1992–2019) metastatic cancer survivors, 82.6% of patients (n = 688,529) died due to the diagnosed cancer, while 17.4% (n = 145,006) died of competing causes. Patients with lung, pancreas, esophagus, and stomach tumors are the most likely to die of their metastatic cancer, while those with prostate and breast cancer have the lowest likelihood. The median survival time among patients living with metastases is 10 months; our Fine and Gray competing risk model predicts 1 year survival with area under the receiver operating characteristic curve of 0.754 (95% CI [0.754, 0.754]). Leading non-cancer deaths are heart disease (32.4%), chronic obstructive and pulmonary disease (7.9%), cerebrovascular disease (6.1%), and infection (4.1%).

Studying survivorship and causes of death in patients with metastatic cancer remains an important task. Here, the authors characterise the causes of death in over a million patients with metastatic cancer, and predict the risk of death after diagnosis due to cancer-related or other causes.

Details

Title
Causes of death among people living with metastatic cancer
Author
Mani, Kyle 1 ; Deng, Daxuan 2 ; Lin, Christine 3 ; Wang, Ming 4   VIAFID ORCID Logo  ; Hsu, Melinda L. 5 ; Zaorsky, Nicholas G. 6   VIAFID ORCID Logo 

 Albert Einstein School of Medicine, Bronx, USA (GRID:grid.501448.c); University Hospitals Seidman Cancer Center and Case Western Reserve University School of Medicine, Department of Radiation Oncology, Cleveland, USA (GRID:grid.473817.e) (ISNI:0000 0004 0418 9795) 
 Penn State College of Medicine, Department of Public Health Sciences, Hershey, USA (GRID:grid.458418.4) 
 Penn State Cancer Institute, Department of Radiation Oncology, Hershey, USA (GRID:grid.458418.4); University Hospitals Seidman Cancer Center and Case Western Reserve University School of Medicine, Department of Radiation Oncology, Cleveland, USA (GRID:grid.473817.e) (ISNI:0000 0004 0418 9795) 
 Case Western Reserve University, Department of Population and Quantitative Health Sciences, School of Medicine, Cleveland, USA (GRID:grid.67105.35) (ISNI:0000 0001 2164 3847) 
 University Hospitals Seidman Cancer Center and Case Western Reserve University School of Medicine, Division of Hematology and Oncology, Cleveland, USA (GRID:grid.473817.e) (ISNI:0000 0004 0418 9795) 
 University Hospitals Seidman Cancer Center and Case Western Reserve University School of Medicine, Department of Radiation Oncology, Cleveland, USA (GRID:grid.473817.e) (ISNI:0000 0004 0418 9795) 
Pages
1519
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2928443620
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.